ROUNDUP 2: Demokraten verlangen Veröffentlichung von Muellers Bericht

Paion - Filings in US and Japan in next six months

Donnerstag, 07.02.2019 14:21

Paion and partner Cosmo took an important step towards a US filing for its ultra-short-acting sedative/anaesthetic remimazolam, with the completion of a successful pre-NDA meeting in July. Filing in Japan (via partner Mundipharma) is expected before the end of 2018. Paion progressed towards its goal of self-commercialising remimazolam in Europe with the initiation of a Phase III study in general anaesthesia (GA) in July. The company is funded beyond top-line data from the EU Phase III trial expected in 2019. Our valuation is €283m or €4.44 per share.